PD-1/PD-L1 Blockade Abrogates a Dysfunctional Innate-adaptive Immune Axis in Critical β-coronavirus Disease

Severe COVID-19 is associated with hyperinflammation and weak T cell responses against SARS-CoV-2. However, the links between those processes remain partially characterized. Moreover, whether and how therapeutically manipulating T cells may benefit patients are unknown. Our genetic and pharmacological evidence demonstrates that the ion channel TMEM176B inhibited inflammasome activation triggered by SARS-CoV-2 and SARS-CoV-2-related murine β-coronavirus. mice infected with murine β-coronavirus developed inflammasome-dependent T cell dysfunction and critical disease, which was controlled by modulating dysfunctional T cells with PD-1 blockers. In critical COVID-19, inflammasome activation correlated with dysfunctional T cells and low monocytic TMEM176B expression, whereas PD-L1 blockade rescued T cell functionality. Here, we mechanistically link T cell dysfunction and inflammation, supporting a cancer immunotherapy to reinforce T cell immunity in critical β-coronavirus disease.

Citing Articles

Single-cell and spatial multi-omics highlight effects of anti-integrin therapy across cellular compartments in ulcerative colitis.

Mennillo E, Kim Y, Lee G, Rusu I, Patel R, Dorman L Nat Commun. 2024; 15(1):1493.

PMID: 38374043 PMC: 10876948. DOI: 10.1038/s41467-024-45665-6.

Anti-PD-L1 therapy altered inflammation but not survival in a lethal murine hepatitis virus-1 pneumonia model.

Curran C, Cui X, Li Y, Jeakle M, Sun J, Demirkale C Front Immunol. 2024; 14:1308358.

PMID: 38259435 PMC: 10801642. DOI: 10.3389/fimmu.2023.1308358.

Virus-Host Protein Interaction Network of the Hepatitis E Virus ORF2-4 by Mammalian Two-Hybrid Assays.

Corneillie L, Lemmens I, Weening K, De Meyer A, Van Houtte F, Tavernier J Viruses. 2023; 15(12).

PMID: 38140653 PMC: 10748205. DOI: 10.3390/v15122412.

Identification of key gene expression associated with quality of life after recovery from COVID-19.

Ren J, Gao Q, Zhou X, Chen L, Guo W, Feng K Med Biol Eng Comput. 2023; 62(4):1031-1048.

PMID: 38123886 DOI: 10.1007/s11517-023-02988-8.

Comprehensive immune profiling reveals that infection activates immune checkpoints during acute T cell immunosuppression.

Louloudes-Lazaro A, Rojas J, Garcia-Garcia I, Rodriguez-Martin D, Morel E, Martin V Front Immunol. 2023; 14:1255803.

PMID: 37920474 PMC: 10619675. DOI: 10.3389/fimmu.2023.1255803.

References

. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med. 2021; 9(3):295-304. PMC: 7825875. DOI: 10.1016/S2213-2600(20)30556-7. View

McLane L, Abdel-Hakeem M, Wherry E . CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Annu Rev Immunol. 2019; 37:457-495. DOI: 10.1146/annurev-immunol-041015-055318. View

Rydyznski Moderbacher C, Ramirez S, Dan J, Grifoni A, Hastie K, Weiskopf D . Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity. Cell. 2020; 183(4):996-1012.e19. PMC: 7494270. DOI: 10.1016/j.cell.2020.09.038. View

Albiges L, Foulon S, Bayle A, Gachot B, Pommeret F, Willekens C . Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort. Nat Cancer. 2022; 1(10):965-975. DOI: 10.1038/s43018-020-00120-5. View

Segovia M, Russo S, Jeldres M, Mahmoud Y, Perez V, Duhalde M . Targeting TMEM176B Enhances Antitumor Immunity and Augments the Efficacy of Immune Checkpoint Blockers by Unleashing Inflammasome Activation. Cancer Cell. 2019; 35(5):767-781.e6. PMC: 6521897. DOI: 10.1016/j.ccell.2019.04.003. View

Stone J, Frigault M, Serling-Boyd N, Fernandes A, Harvey L, Foulkes A . Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020; 383(24):2333-2344. PMC: 7646626. DOI: 10.1056/NEJMoa2028836. View

Campos Codo A, Davanzo G, de Brito Monteiro L, Fabiano de Souza G, Muraro S, Virgilio-da-Silva J . Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis. Cell Metab. 2020; 32(3):498-499. PMC: 7462530. DOI: 10.1016/j.cmet.2020.07.015. View

Martinon F, Burns K, Tschopp J . The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002; 10(2):417-26. DOI: 10.1016/s1097-2765(02)00599-3. View

Ribas A, Wolchok J . Cancer immunotherapy using checkpoint blockade. Science. 2018; 359(6382):1350-1355. PMC: 7391259. DOI: 10.1126/science.aar4060. View

10.

Zheng M, Karki R, Williams E, Yang D, Fitzpatrick E, Vogel P . TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat Immunol. 2021; 22(7):829-838. PMC: 8882317. DOI: 10.1038/s41590-021-00937-x. View

11.

Lee S, Channappanavar R, Kanneganti T . Coronaviruses: Innate Immunity, Inflammasome Activation, Inflammatory Cell Death, and Cytokines. Trends Immunol. 2020; 41(12):1083-1099. PMC: 7561287. DOI: 10.1016/j.it.2020.10.005. View

12.

Gordon A, Mouncey P, Al-Beidh F, Rowan K, Nichol A, Arabi Y . Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med. 2021; 384(16):1491-1502. PMC: 7953461. DOI: 10.1056/NEJMoa2100433. View

13.

Scott A, Dundar F, Zumbo P, Chandran S, Klebanoff C, Shakiba M . TOX is a critical regulator of tumour-specific T cell differentiation. Nature. 2019; 571(7764):270-274. PMC: 7698992. DOI: 10.1038/s41586-019-1324-y. View

14.

Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A . Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2005; 439(7077):682-7. DOI: 10.1038/nature04444. View

15.

Wang E, Mao T, Klein J, Dai Y, Huck J, Jaycox J . Diverse functional autoantibodies in patients with COVID-19. Nature. 2021; 595(7866):283-288. DOI: 10.1038/s41586-021-03631-y. View

16.

Chang K, Svabek C, Vazquez-Guillamet C, Sato B, Rasche D, Wilson S . Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care. 2014; 18(1):R3. PMC: 4056005. DOI: 10.1186/cc13176. View

17.

Aldea M, Michot J, Danlos F, Ribas A, Soria J . Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19. Cancer Discov. 2021; 11(6):1336-1344. DOI: 10.1158/2159-8290.CD-21-0144. View

18.

McClain M, Constantine F, Henao R, Liu Y, Tsalik E, Burke T . Dysregulated transcriptional responses to SARS-CoV-2 in the periphery. Nat Commun. 2021; 12(1):1079. PMC: 7889643. DOI: 10.1038/s41467-021-21289-y. View

19.

Karlsson A, Humbert M, Buggert M . The known unknowns of T cell immunity to COVID-19. Sci Immunol. 2020; 5(53). DOI: 10.1126/sciimmunol.abe8063. View

20.

Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J . Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020; 26(6):842-844. DOI: 10.1038/s41591-020-0901-9. View